A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria

• •Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. A list of key criteria is listed below:
• •Onset of symptoms less than 3 years prior to study entry.
• •Forced Vital Capacity (FVC) at least 70% of that predicted for age and height.
• •Stable dose of riluzole if undergoing treatment with this agent.
• •For females: Not be of childbearing potential or agree to use adequate birth control during the study.